1. Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72(10):1938-1956

2. Chadha GK, Ahmadieh A, Kumar S, Sedghizadeh PP. Osseointegration of dental implants and osteonecrosis of the jaw in patients treated with bisphosphonate therapy: a systematic review. J Oral Implantol 2013;39(4):510-520

3. S hannon J, Shannon J, Modeelvsky S, Grippo AA. Bisphosphonates and osteonecrosis of the jaw. J Am Geriatr Soc 2011;59(12):2350-2355

4. Al-Sabbagh M, Thomas MV, Bhavsar I, De Leeuw R. Effect of Bisphosphonate and Age on Implant Failure as Determined by Patient-Reported Outcomes. J Oral Implantol 2015;41(6):e287-291

5. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302(3):1055-1061

6. Otto S, Pautke C, Van den Wyngaert T, et al. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev 2018;69:177-187

7. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22(10):1479-1491

8. Watts NB, Grbic JT, Binkley N, et al. Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years. J Clin Endocrinol Metab 2019;104(6):2443-2452

9. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws AAoO, Maxillofacial S. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65(3):369-376

10. Lazarovici TS, Yahalom R, Taicher S, et al. Bisphosphonate-related osteonecrosis of the jaw associated with dental implants. J Oral Maxillofac Surg 2010;68(4):790-796

11. Limones A, Saez-Alcaide LM, Diaz-Parreno SA, et al. Medicationrelated osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis. Med Oral Patol Oral Cir Bucal 2020;25(3):e326-e336

12. Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract 2012;66(12):1139-1146

13. Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg 2010;68(5):959-963

14. Poxleitner P, Engelhardt M, Schmelzeisen R, Voss P. The Prevention of Medication-related Osteonecrosis of the Jaw. Dtsch Arztebl Int 2017;114(5):63-69

15. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012;23(5):1341-1347

16. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006;12(20 Pt 2):6222s-6230s

17. Madrid C, Sanz M. What impact do systemically administrated bisphosphonates have on oral implant therapy? A systematic review. Clin Oral Implants Res 2009;20 Suppl 4:87-95

18. Esposito M, Hirsch JM, Lekholm U, Thomsen P. Biological factors contributing to failures of osseointegrated oral implants. (I). Success criteria and epidemiology. Eur J Oral Sci 1998;106(1):527-551

19. Giovannacci I, Meleti M, Manfredi M, et al. Medication-Related Osteonecrosis of the Jaw Around Dental Implants: Implant Surgery-Triggered or Implant Presence-Triggered Osteonecrosis? J Craniofac Surg 2016;27(3):697-701

20. Minsk L, Polson AM. Dental implant outcomes in postmenopausal women undergoing hormone replacement. Compend Contin Educ Dent 1998;19(9):859-862, 864; quiz 866

21. Yajima N, Munakata M, Fuchigami K, et al. Influence of Bisphosphonates on Implant Failure Rates and Characteristics of Postmenopausal Woman Mandibular Jawbone. J Oral Implantol 2017;43(5):345-349

22. Cabrales-Salgado RJ, Shibli JA, Piattelli A, et al. Mechanical Properties of the Mandible in Postmenopausal Women Under Aledronate Treatment. J Int Acad Periodontol 2020;22(4):231-235

23. Fliefel R, Troltzsch M, Kuhnisch J, et al. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg 2015;44(5):568-585

24. Sher J, Kirkham-Ali K, Luo D, et al. Dental Implant Placement in Patients with a History of Medications Related to Osteonecrosis of the Jaws: A Systematic Review. J Oral Implantol 2020

25. Marx RE, Cillo JE, Jr., Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65(12):2397-2410

26. Jacobsen C, Metzler P, Rossle M, et al. Osteopathology induced by bisphosphonates and dental implants: clinical observations. Clin Oral Investig 2013;17(1):167-175

27. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate induced exposed bone (osteonecrosis/osteopetrosis) of the jaws:risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63(11):1567-1575

28. Aljohani S, Fliefel R, Ihbe J, et al. What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review. J Craniomaxillofac Surg 2017;45(9):1493-1502

29. Otto S, Troltzsch M, Jambrovic V, et al. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration:A trigger for BRONJ development? J Craniomaxillofac Surg 2015;43(6):847-854

30. Kos M, Junka A, Smutnicka D, et al. Bisphosphonates enhance bacterial adhesion and biofilm formation on bone hydroxyapatite. J Craniomaxillofac Surg 2015;43(6):863-869

31. Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015;30(1):3-23

32. AlDhalaan NA, BaQais A, Al-Omar A. Medication-related Osteonecrosis of the Jaw: A Review. Cureus 2020;12(2):e6944

33. Stavropoulos A, Bertl K, Pietschmann P, et al. The effect of antiresorptive drugs on implant therapy: Systematic review and metaanalysis. Clin Oral Implants Res 2018;29 Suppl 18:54-92

34. Martin DC, O'Ryan FS, Indresano AT, et al. Characteristics of implant failures in patients with a history of oral bisphosphonate therapy. J Oral Maxillofac Surg 2010;68(3):508-514

35. Tallarico M, Canullo L, Xhanari E, Meloni SM. Dental implants treatment outcomes in patient under active therapy with alendronate:3-year follow-up results of a multicenter prospective observational study. Clin Oral Implants Res 2016;27(8):943-949

36. Pogrel MA, Ruggiero SL. Previously successful dental implants can fail when patients commence anti-resorptive therapy-a case series. Int J Oral Maxillofac Surg 2018;47(2):220-222

37. Troeltzsch M, Cagna D, Stahler P, et al. Clinical features of periimplant medication-related osteonecrosis of the jaw: Is there an association to peri-implantitis? J Craniomaxillofac Surg 2016;44(12):1945-1951

38. Pichardo SEC, van der Hee JG, Fiocco M, et al. Dental implants as risk factors for patients with medication-related osteonecrosis of the jaws (MRONJ). Br J Oral Maxillofac Surg 2020;58(7):771-776

39. Kwon TG, Lee CO, Park JW, et al. Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment. Clin Oral Implants Res 2014;25(5):632-640

40. Hoefert S, Schmitz I, Tannapfel A, Eufinger H. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and nonsymptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Investig 2010;14(3):271-284

41. Bedogni A, Bettini G, Totola A, et al. Oral bisphosphonate-associated osteonecrosis of the jaw after implant surgery: a case report and literature review. J Oral Maxillofac Surg 2010;68(7):1662-1666

42. Marx RE. A decade of bisphosphonate bone complications: what it has taught us about bone physiology. Int J Oral Maxillofac Implants 2014;29(2):e247-258

43. Grant BT, Amenedo C, Freeman K, Kraut RA. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg 2008;66(2):223-230

44. Nisi M, La Ferla F, Karapetsa D, et al. Risk factors influencing BRONJ staging in patients receiving intravenous bisphosphonates: a multivariate analysis. Int J Oral Maxillofac Surg 2015;44(5):586-591

45. Otto S, Schreyer C, Hafner S, et al. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg 2012;40(4):303-309

46. Fehm T, Beck V, Banys M, et al. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 2009;112(3):605-609

47. Papadakis I, Spanou A, Kalyvas D. Success rate and safety of dental implantology in patients treated with antiresorptive medication: A systematic review. J Oral Implantol 2020

48. Mozzati M, Arata V, Giacomello M, et al. Failure risk estimates after dental implants placement associated with plasma rich in growth factor-Endoret in osteoporotic women under bisphosphonate therapy. J Craniofac Surg 2015;26(3):749-755

49. de-Freitas NR, Lima LB, de-Moura MB, et al. Bisphosphonate treatment and dental implants: A systematic review. Med Oral Patol Oral Cir Bucal 2016;21(5):e644-651

50. Kasai T, Pogrel MA, Hossaini M. The prognosis for dental implants placed in patients taking oral bisphosphonates. J Calif Dent Assoc 2009;37(1):39-42

51. Tallarico M, Vaccarella A, Marzi GC. Clinical and radiological outcomes of 1- versus 2-stage implant placement: 1-year results of a randomised clinical trial. Eur J Oral Implantol 2011;4(1):13-20

52. American Dental Association Council on Scientific A. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc 2006;137(8):1144-1150

53. Yip JK, Borrell LN, Cho SC, et al. Association between oral bisphosphonate use and dental implant failure among middle-aged women. J Clin Periodontol 2012;39(4):408-414

54. Markiewicz MR, Margarone JE, 3rd, Campbell JH, Aguirre A. Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge. J Am Dent Assoc 2005;136(12):1669-1674

55. Kumar MN, Honne T. Survival of dental implants in bisphosphonate users versus non-users: a systematic review. Eur J Prosthodont Restor Dent 2012;20(4):159-162

56. Sim Ie W, Sanders KM, Borromeo GL, et al. Declining Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Cancer. J Clin Endocrinol Metab 2015;100(10):3887-3893

57. Kim JY, Choi H, Park JH, et al. Effects of anti-resorptive drugs on implant survival and peri-implantitis in patients with existing osseointegrated dental implants: a retrospective cohort study. Osteoporos Int 2020;31(9):1749-1758